Laboratory: increase Prothrombin time (PT).
实验室检查：凝血酶原时间(PT)延长。
Used for biochemical studies, to prevent the prothrombin into thrombin.
用于生化研究，防止凝血酶原转变成凝血酶。
Prothrombin G20210A mutation can lead to plasma prothrombin level increase.
凝血酶原基因g20210a突变，可导致血浆凝血酶原水平升高。
Objective: to investigate the part influence factors of prothrombin time assay.
目的：探讨凝血酶原时间测定的部分影响因素。
When the tissue damage, the release of thromboplastin to prothrombin into thrombin.
当组织损伤时，释放出凝血致活酶，把凝血酶原变成凝血酶。
Objective to explore effects of blood platelets and prothrombin time on mifepristone.
目的探讨米非司酮对血小板、血浆凝血酶原时间的影响。
Results No prothrombin gene G20210A mutation was found in both patients and controls.
结果所有受检者均未发现凝血酶原G20210A基因突变。
In contrast, there wag no abnormal prothrombin in the rat plasma during its liver regeneration.
诱癌早期的大鼠血浆即出现了高水平异常凝血酶原，它可用于肝癌的早期诊断。
Conclusion Prothrombin 20210a gene mutation may increase genetic susceptibility of gastric cancer.
结论凝血酶原突变基因20210A可能增加了胃癌的遗传易感性。
Patients with hypoproteinemia or prolonged prothrombin time (PT) were often accompanied by hypocalcemia.
低蛋白血症和PT延长的病例伴有低血钙较常见。
The platelet count's down to a thousand. Prothrombin time's way up at thirty, and he's got fibrin degradation products.
血小板计数下降到1000，凝血原酶时间上升到30，而且血液中有纤维蛋白降解产物。
Objective: To study the relationship between prothrombin coagulative activity and the prognosis of patients with liver cirrhosis.
目的：研究凝血酶原活性与肝硬化病人预后的关系。
The majority of patients with ascites due to cirrhosis have prolongation of the prothrombin time and some degree of thrombocytopenia.
大多数肝硬化腹水的患者凝血酶原时间延长并有一定程度的血小板减少。
However, there was no significant difference in the total bilirubin and prothrombin time in either group during the observation periods.
然而，观察期间在总胆红素和凝血酶原时间方面两组之间没有显著差异。
Objective To evaluate the treatment of plasma exchange(PE) in patients with chronic severe hepatitis based on prothrombin activity(PTA).
目的探讨根据凝血酶原活动度（PTA）预测重型肝炎高胆红素血症行血浆置换的临床疗效。
The production method has the advantages that content of the product prothrombin and oligosaccharide is less, and the nutrition is rich.
本发明具有制作出的产品凝血素和寡糖含量较少、营养较丰富的优点。
The prothrombin time(PT) and the active partial thromboplastin time(APTT) were measured by the ACL- 200 antomatic blood agglutination instrument.
用ACL-200型血液凝集仪测定大鼠凝血酶原时间（PT）和部分凝血活酶时间（APTT）。
Objective:To prepare a monoclonal antibody against prothrombin fragment 1+2(F1+2) and study its diagnostic effect in patients with thromboembolism.
前言： 目的：自制凝血酶原片段F1+2单克隆抗体，探讨其在血栓性疾病中的诊断作用。
Objective: to monitor the curative effect of oral warfarin for the patients after heart mechanical valve displacement by the prothrombin time (PT).
目的评价采用凝血酶原时间(PT)监测心脏机械型瓣膜置换术后患者口服华法林治疗效果的意义。
We found ABP prolonged coagulation time (CT) in mice, increased plasma prothrombin time (PT) and kaolin partial thromboplastin time (KPTT) in rats.
发现怀牛膝多糖a BP能延长小鼠凝血时间(CT)、大鼠血浆凝血酶原时间(PT)、白陶土部分凝血活酶时间(KPTT)。
The result of liver function, renal function, electrolyte, prothrombin time activity (PTa), blood routine before and after the treatment were analyzed.
比较了血浆置换前后患者临床症状、肝肾功能、电解质、凝血酶原活动度、血常规变化等。
Prothrombin time and International Normalized Ratio should be carefully monitored in patients concurrently administered ISTODAX and Coumadin derivatives.
凝血酶原时间和国际标准化比值应仔细监测患者同时管理ISTODAX和香豆衍生物。
PurposeTo study on the quality of human prothrombin complex concentrate so as to establish the same quality standard as the international standard of PCC.
目的通过对国产人凝血酶原复合物(PCC)质量的研究，建立与国际接规的质量标准。
There was no significant difference in platelet count, plasma prothrombin time and plasma viscosity between treatment group and control group ( P > 0.05) .
治疗组血小板计数、凝血酶原时间及血浆黏度变化与对照组相似（P>0.05）。
Methods Prothrombin fragments 1 and 2 (F1+2), fibrinopeptide A (FPA), soluble fibrin monomer complex(SFMC) were examined by enzyme linked immunoassay(ELISA);
方法采用酶联免疫分析法测定凝血酶原片段1+2 （F1+2 ）、纤维蛋白肽A（FPA）、可溶性纤维蛋白单体复合物（SFMC） ；
Technical conditions for adsorption and separation of prothrombin complex concentrates from human plasma with CG-6 macroporous anion-exchange resin were optimized.
优化了CG - 6型大孔阴离子交换树脂从人血浆中吸附和分离凝血酶原复合物的工艺条件。
[Packaging] Borosilicate glass vial, sealed with bromobutyl rubber stopper, packaging of 1 set per carton. 1 set contains a vial of human prothrombin complex, and solution.
硼硅玻璃模制注射剂瓶、溴化丁基橡胶塞包装。1套/盒。 1套包含人凝血酶原复合物1瓶，人凝血酶原复合物溶解液1瓶。
Results It was more prominent of decrease icterus index, increase seralbumin, the activity of prothrombin and the effective rate in the trial group than in the control group.
结果治疗组在降酶、退黄，提高血清白蛋白、升高凝血酶原活动度，以及治疗有效率等方面均优于对照组，差异具有显著性。
Objective To explore the clinical significance of platelet, prothrombin time , activated partial thromboplastin time , thrombin time , plasma fibrinogen for parturient women.
目的探讨临产孕妇血小板、凝血酶原时间、活化部分凝血活酶时间、凝血酶时间、纤维蛋白原检测的临床意义。
Purpose to establish the preparation procedure of human prothrombin complex concentrate (PCC) by using two-step gel chromatography to obtain high purity and high security product.
目的应用两步凝胶色谱法制备高纯度、高安全性的人凝血酶原复合物(PCC)制剂。
应用推荐